Assessment of lisavanbulin (BAL101553) as an anti-lymphoma agent
F. Spriano, L. Aresu, L. Cascione, G. Risi, A. J. Arribas, S. Napoli, A. Rinaldi, N. Forster-Gross, F. Bachmann, M. Engelhardt, H. Lane, F. Bertoni
This study evaluates lisavanbulin's anti-lymphoma activity and EB1 expression in DLBCL, showing potent in vitro cytotoxicity and potential clinical relevance.
bioRxiv · Dec 31, 2022 · PreprintCancer Biology